Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C-pyruvate MRI in Infiltrating Gliomas
NCT04772456Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Aug 2020
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized 13C-pyruvate in glioma, sponsored by University of Maryland, Baltimore. Primary endpoint: Accuracy of metabolic MRI to diagnose Glioma at 3 years. Started Aug 2020; status: recruiting.
02
Drugs
hyperpolarized 13C-pyruvate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04772456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772456.